EARLY SERUM HEPATITIS B VIRUS LARGE SURFACE PROTEIN LEVEL: A STRONG PREDICTOR OF VIROLOGICAL RESPONSE FOR PEGINTERFERON, BUT NOT FOR ENTECAVIR, IN HBeAg-POSITIVE CHRONIC HEPATITIS B

被引：0
|
作者：
Zhu, X. J. [1 ]
Gong, Q. M. [1 ]
Yu, D. M. [1 ]
Zhang, D. H. [1 ]
Gu, L. L. [1 ]
Han, Y. [1 ]
Chen, J. [1 ]
Zhang, X. X. [1 ]
机构：
[1] Shanghai Jiao Tong Univ, Dept Infect Dis, Ruijin Hosp, Sch Med, Shanghai 200030, Peoples R China
来源：
JOURNAL OF HEPATOLOGY | 2013年 / 58卷
关键词：
D O I：
10.1016/S0168-8278(13)60785-0
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
783
引用
收藏
页码：S319 / S319
页数：1
相关论文
共 50 条
  • [41] COST-EFFECTIVENESS OF PEGINTERFERON ALFA-2A VERSUS ENTECAVIR IN THE TREATMENT OF HBEAG-POSITIVE CHRONIC HEPATITIS B IN CHINA
    Sheng, F.
    VALUE IN HEALTH, 2009, 12 (07) : A428 - A429
  • [42] Correlation of Serum Hepatitis B Surface Antigen Level With Response to Entecavir in Naive Patients With Chronic Hepatitis B
    Lee, Myoung Hee
    Lee, Da Mi
    Kim, Soon Sun
    Cheong, Jae Youn
    Cho, Sung Won
    JOURNAL OF MEDICAL VIROLOGY, 2011, 83 (07) : 1178 - 1186
  • [43] Baseline serum hepatitis B core antibody level predicts HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B after antiviral treatment
    Zhao, Xiang-An
    Wang, Jian
    Liu, Jiacheng
    Chen, Guangmei
    Yan, Xiaomin
    Jia, Bei
    Yang, Yue
    Liu, Yong
    Gu, Da
    Zhang, Zhaoping
    Xiang, Xiaoxing
    Huang, Rui
    Wu, Chao
    ANTIVIRAL RESEARCH, 2021, 193
  • [44] On-treatment HBV DNA dynamics predict virological breakthrough in entecavir-treated HBeAg-positive chronic hepatitis B
    Huang, Yi-Jie
    Chang, Chi-Sen
    Peng, Yen-Chun
    Yeh, Hong-Zen
    Yang, Sheng-Shun
    PLOS ONE, 2017, 12 (03):
  • [45] Serum Alpha-Fetoprotein as a Predictor of Liver Fibrosis in HBeAg-Positive Chronic Hepatitis B Patients
    Yang, Kai
    Pan, Ying
    Liu, Liwei
    Sun, Beibei
    Shi, Wei
    MEDICINA-LITHUANIA, 2023, 59 (05):
  • [46] Performance of Hepatitis B Core-Related Antigen Versus Hepatitis B Surface Antigen and Hepatitis B Virus DNA in Predicting HBeAg-positive and HBeAg-negative Chronic Hepatitis
    Zhang, Zhan-qing
    Wang, Yan-bing
    Lu, Wei
    Liu, Dan-ping
    Shi, Bi-sheng
    Zhang, Xiao-nan
    Huang, Dan
    Li, Xiu-fen
    Zhou, Xin-lan
    Ding, Rong-rong
    ANNALS OF LABORATORY MEDICINE, 2019, 39 (01) : 67 - 75
  • [47] Addition of (pegylated) interferon to entecavir increases response in treatment naive HBeAg-positive patients with chronic hepatitis B
    Liem, S.
    van Campenhout, M. J.
    Chi, H.
    Brouwer, W. P.
    Xie, Q.
    Qi, X.
    Liang, C.
    Tabak, F.
    Hansen, B. E.
    Janssen, H. L.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S692 - S692
  • [48] Dynamic changes of cytokine profiles and virological markers during 48 weeks of entecavir treatment for HBeAg-positive chronic hepatitis B
    Li, Minghui
    Gao, Yuanjiao
    Yang, Liu
    Lin, Yanjie
    Deng, Wen
    Jiang, Tingting
    Bi, Xiaoyue
    Lu, Yao
    Zhang, Lu
    Shen, Ge
    Liu, Ruyu
    Wu, Shuling
    Chang, Min
    Xu, Mengjiao
    Hu, Leiping
    Song, Rui
    Jiang, Yuyong
    Yi, Wei
    Xie, Yao
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [49] Decline in Quantitative Serum HBsAg Level during Consolidation Therapy Following HBeAg Loss in HBeAg-positive Chronic Hepatitis B Patients Treated with Entecavir
    Su, Wen-Pang
    Peng, Cheng-Yuan
    Lai, Hsueh-Chou
    Lin, Chia-Hsin
    Chuang, Po-Heng
    Chen, Sheng-Hung
    HEPATOLOGY, 2014, 60 : 1102A - 1103A
  • [50] Virological response to antiviral therapy at week 12 indicates a great reduction of intrahepatic hepatitis B virus DNA and cccDNA in HBeAg-positive chronic hepatitis B patients
    Lu, H. Y.
    Zhuang, L. W.
    Yu, Y. Y.
    Si, C. W.
    JOURNAL OF VIRAL HEPATITIS, 2010, 17 : 59 - 65
12345